Get the Stockscreener App
33.47
2.16%
-0.74
Pre-market:
34.00
0.53
+1.58%
Agios Pharmaceuticals Inc stock is traded at $33.47, with a volume of 939.12K.
It is down -2.16% in the last 24 hours and down -17.46% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$34.21
Open:
$34.35
24h Volume:
939.12K
Relative Volume:
0.85
Market Cap:
$2.00B
Revenue:
$66.05M
Net Income/Loss:
$-422.60M
P/E Ratio:
-4.6159
EPS:
-7.251
Net Cash Flow:
$-384.73M
1W Performance:
+4.76%
1M Performance:
-17.46%
6M Performance:
+19.71%
1Y Performance:
-8.58%
1-Day Range:
$33.31
$34.65
1-Week Range:
$31.55
$34.65
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
33.47 | 2.04B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Reiterated | H.C. Wainwright | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO) - The Globe and Mail
Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sei Investments Co. Acquires 49,198 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Responsive Playbooks and the AGIO Inflection - Stock Traders Daily
FARALLON CAPITAL MANAGEMENT LLC Adds to Agios Pharmaceuticals In - GuruFocus
Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds - Sahm
AGIO Maintained by JP Morgan -- Price Target Raised to $34 - GuruFocus
Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $34.00 at JPMorgan Chase & Co. - MarketBeat
Agios Pharmaceuticals (AGIO) Chief Medical Officer Sarah Gheuens Sells 30,000 Shares - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 30,000 Shares - MarketBeat
Agios Pharmaceuticals (AGIO) CMO sells 30,000 shares in plan trade - Stock Titan
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors - simplywall.st
Agios Pharmaceuticals Inc (AGIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AGIO (NASDAQ: AGIO) insider Sarah Gheuens files to sell 30,000 shares - Stock Titan
Dimensional Fund Advisors LP Increases Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals (AGIO) Stock Analysis: High Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Farallon Capital (AGIO) discloses 5.9M-share, 9.9% position in Agios - Stock Titan
Research Analysts Set Expectations for AGIO Q3 Earnings - MarketBeat
Seven Fleet Capital Management LP Has $7.09 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Price to sales forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO - TradingView
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $39 - Moomoo
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $39 to $55 - Moomoo
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year - Yahoo Finance
AGIO: Q2 2026 delivered $44.7M revenue, strong AQVESME launch, and pipeline progress with ~$1B cash - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - PR Newswire
Agios Pharmaceuticals: Q2 Earnings Snapshot - KTVB
Agios Pharmaceuticals Q2 Loss Narrows as Revenue Increases - marketscreener.com
Agios Pharmaceuticals, Inc. $AGIO Holdings Lowered by ADAR1 Capital Management LLC - MarketBeat
AGIO|Agios Pharmaceuticals Inc|Price:36.308|Chg%:-0.662 - TradingKey
Understanding the Setup: (AGIO) and Scalable Risk - Stock Traders Daily
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo Finance
Law firm investigates Agios Pharmaceuticals ove... - Pluang
Agios Pharmaceuticals Inc (AGIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Agios Pharmaceuticals Inc (AGIO) Cash Flow - TradingKey
Agios Pharmaceuticals Inc (AGIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Agios Pharmaceuticals Inc (AGIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Agios Pharmaceuticals Inc (AGIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agios Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AGIO - TradingView
Agios Pharmaceuticals Inc. (AGIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Knott David M Jr Has $3.15 Million Stake in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Imunon (IMNN) - The Globe and Mail
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Agios Pharmaceuticals (AGIO) to Post Quarterly Earnings on Thursday - MarketBeat
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Sahm
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program - Yahoo Finance
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):